scholarly journals Performance and usability evaluation of novel intradermal injection device Immucise™ and reanalysis of intradermal administration trials of influenza vaccine for the elderly

Vaccine ◽  
2022 ◽  
Author(s):  
Sakiko Shimizu ◽  
Ryo Tanaka ◽  
Eriko Itoh ◽  
Minami Maekawa-Matsuura ◽  
Yoichiro Iwase
2005 ◽  
Vol 2 (1) ◽  
pp. 35-38
Author(s):  
Maliheh Metanat ◽  
Masoud Salehi . ◽  
Batool Sharifi-Mood . ◽  
Mohammad-Reza Safai .

2007 ◽  
Vol 12 (20) ◽  
Author(s):  
B Nunes ◽  
I Falcao ◽  
A Machado ◽  
E Rodrigues ◽  
J Marinho Falcao

Vaccination of the elderly (>=65 years of age) against influenza is recommended in all European countries


2000 ◽  
Vol 125 (2) ◽  
pp. 393-397 ◽  
Author(s):  
Y. DEGUCHI ◽  
Y. TAKASUGI ◽  
K. NISHIMURA

Influenza vaccine effect on the occurrence and severity of influenza virus infection in a population residing in nursing homes for the elderly was studied as a cohort study during an influenza A (H3N2) epidemic in Japan. Of 22462 individuals living in 301 welfare nursing homes, 10739 voluntarily received inactivated, sub-unit trivalent influenza vaccine in a programme supported by the Osaka Prefectural Government. There were statistically significantly fewer cases of influenza, hospital admissions due to severe infection, and deaths due to influenza in the vaccinated cohort compared to the unvaccinated controls. No serious adverse reactions to vaccination were recorded. Thus influenza vaccination is effective for preventing influenza disease in persons aged 65 years and over, and should be an integral part of the care of this population residing in nursing homes.


Nutrients ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2740
Author(s):  
Pureum Sun ◽  
Yeeun Kim ◽  
Hoyoung Lee ◽  
Jihyun Kim ◽  
Bok Kyung Han ◽  
...  

Despite the advancements in vaccination research and practices, influenza viruses remain a global health concern. Inducing a robust immune response by vaccination is especially challenging in the elderly, the immunocompromised, and persons with chronic illnesses. Polysaccharides derived from food may act as a safe and readily accessible means to boost the immune system during vaccination. In this study, we investigated whether crude polysaccharides derived from carrot pomace (CPP) could stimulate innate immune cell function and promote influenza vaccine immunogenicity. In bone marrow-derived dendritic cells (BMDCs), CPP increased the fraction of CD11c+MHCII+ cells and the expression of co-stimulatory molecules CD40 and CD80, indicative of enhanced maturation and activation. Functionally, CPP-treated BMDCs promoted inflammatory cytokine production in splenic lymphocytes. In a mouse model of immunosuppression induced by cyclophosphamide, animals given CPP before and after an influenza vaccine challenge showed increased frequencies of dendritic cells and natural killer cells in the spleen, in addition to the recovery of vaccine-specific antibody titers. Moreover, innate myeloid cells in CPP-fed mice showed evidence of phenotypic modification via markedly enhanced interleukin(IL)-12 and interferon(IFN)-γ production in response to lipopolysaccharide(LPS) stimulation ex vivo. Our findings suggest that the administration of carrot pomace polysaccharides can significantly enhance the efficacy of influenza vaccination.


Vaccine ◽  
2019 ◽  
Vol 37 (36) ◽  
pp. 5314-5322 ◽  
Author(s):  
Massimo Fabiani ◽  
Enrico Volpe ◽  
Maurizio Faraone ◽  
Antonino Bella ◽  
Caterina Rizzo ◽  
...  

Vaccine ◽  
2017 ◽  
Vol 35 (4) ◽  
pp. 513-520 ◽  
Author(s):  
Alexander Domnich ◽  
Lucia Arata ◽  
Daniela Amicizia ◽  
Joan Puig-Barberà ◽  
Roberto Gasparini ◽  
...  

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 704
Author(s):  
Laura Sánchez de Prada ◽  
Iván Sanz Muñoz ◽  
Javier Castrodeza Sanz ◽  
Raúl Ortiz de Lejarazu Leonardo ◽  
José María Eiros Bouza

Background: vaccination is the best approach to prevent influenza infections so far. Serological studies on the effect of different vaccine types are important to address vaccination campaigns and protect our population. In our study, we compared the serological response against influenza A subtypes using the non-adjuvanted influenza vaccine (NAIV) in adults and the elderly and the adjuvanted influenza vaccine (AIV) in the elderly. Methods: We performed a retrospective analysis by hemagglutination inhibition assay (HI) of serum samples right before and 28 days after seasonal influenza vaccination during the 1996–2017 seasons. Conclusions: The AIV presents better performance against the A(H3N2) subtype in the elderly whereas the NAIV induces a better response against A(H1N1)pdm09 in the same group.


Sign in / Sign up

Export Citation Format

Share Document